BioSpace News Archive

Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, announced that all items of business were approved at its virtual Annual General and Special Meeting of Shareholders.

Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents per share on the $0.10 par value common stock of the company.

Centogene N.V. announced that it has received a written notification from the Nasdaq Stock Market LLC dated June 8, 2023, indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares set forth in the Nasdaq Rules for continued listing on the Nasdaq Global Market.

Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, will host an Investor Day on Thursday, June 29, 2023 beginning at 8 a.m. EDT in New York City, and will also be available via a live webcast.

Enzo Biochem, Inc., a pioneering biosciences and diagnostics company, filed its Form 10-Q for the third quarter ended April 30, 2023 of Fiscal Year 2023.

Seagen Inc. announced an update to the U.S. Prescribing Information for ADCETRIS® to include six-year overall survival results from the phase 3 ECHELON-1 clinical trial of ADCETRIS plus combination chemotherapy in patients with previously untreated Stage III or IV classical Hodgkin lymphoma compared to chemotherapy alone.

Editas Medicine, Inc., a clinical-stage genome editing company, announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.

Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced the pricing of an underwritten public offering of common stock.

CNS Pharmaceuticals, Inc. announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest on Wednesday, June 21, 2023 at 2:30 PM ET.

Vial, a global tech-driven CRO providing next-generation clinical trial management services, has partnered with Nielsen BioSciences, Inc. (Nielsen), a privately-held biopharmaceutical company based in San Diego, CA, to study the safety and efficacy of CANDIN® for the treatment of common warts.